The 62 references in paper O. Kuzmin B., M. Pugaeva O., V. Zhezha V., О. Кузьмин Б., М. Пугаева О., В. Жежа В. (2006) “НЕФРОПРОТЕКТИВНАЯ ТЕРАПИЯ ГИПЕРТЕНЗИВНЫХ БОЛЬНЫХ С ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК: ЕСТЬ ЛИ В НЕЙ МЕСТО ДЛЯ β-АДРЕНОБЛОКАТОРОВ ТРЕТЬЕГО ПОКОЛЕНИЯ И АГОНИСТОВ I1-ИМИДАЗОЛИНОВЫХ РЕЦЕПТОРОВ? // NEPHROPROTECTIVE THERAPY OF HYPERTENSIVE PATIENTS WITH CHRONIC KIDNEY DISEASE: IS THERE A PLACE FOR THE THIRD GENERATION OF β-ADRENORECEPTOR BLOCKERS AND I1-IMIDAZOLINE RECEPTOR AGONISTS?” / spz:neicon:nefr:y:2006:i:2:p:18-27

1
Chobanian A, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension
(check this in PDF content)
2
03; 42 (6): 1206-1252 2. Guidelines Committee. 2003 European Society of hypertension / European Society of cardiology guidelines for management of arterial hypertension. J Hypertens 2003; 21 (6): 1011-1053
(check this in PDF content)
3
Комитет экспертов ВНОК. Профилактика, диагнос­ тика и лечение артериальной гипертонии. Российские ре­ комендации (второй пересмотр). Кардиоваскулярная терапия и профилактика 2004; 6 [Приложение]: 3-19
(check this in PDF content)
4
Ruggenenti P, Perna A, Loziga G et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN 2): multicentre, randomized controlled trial. Lancet 2005; 365 (9463): 939-946
(check this in PDF content)
5
Sato A, Saruta T. Aldosterone escape during angiotensin­ converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29 (1): 13-21
(check this in PDF content)
6
Schjoedt KJ, Andersen S, Rossing P et al. Aldosterone escape during blockade of renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47 (11): 1936-1939.
(check this in PDF content)
7
Eppel GA, Malpas SC, Denton KM, Evans RG. Neural control of renal medullary perfusion. Clin Exp Pharmacol Physiol 2004; 31 (5-6): 387-396
(check this in PDF content)
8
Barajas L, Powers K, Wang P Innervation of renal cortical tubules: a quantitative study. Am J Physiol 1984; 247 (1): F30- F60
(check this in PDF content)
9
Cohen HT, Takemoto F, Satoh T, Katz AI. Renal adrenergic receptors: localization of 125Iprasosin binding sites along the microdissected rat nephron. Can J Physiol Pharmacol 1992; 70 (7): 1016-1020
(check this in PDF content)
10
Struyker-Boudier HA, Janssen BJ, Smiths JF. Adrenoreceptors in the kidney: localization and pharmacology. Clin Exp Hypertens 1987; A9, [Suppl 1]: 135-150
(check this in PDF content)
11
Wang TT, Chen X, Wu XH et al. Molecular mechanism of action of isoprotorenol on the expression of angiotensinogen gene in opossum kidney proximal tubular cells. Kidney Int 1999; 55 (5): 1713-1723
(check this in PDF content)
12
Wolf G, Helmchen U, Stahl RA. Isoprotorenol stimulates tubular DNA replication in mice. Nephrol Dial Transplant 1996; 11 (11): 2288-2292
(check this in PDF content)
13
Nakamura A, Imaizumi A, Yanagawa Y et al. Suppression of tumor necrosis factor-alpha by l2-adrenoceptor activation: role of mitogen-activated protein kinases in renal mesangial cells. Inflam Res 2003; 52 (1): 26-31
(check this in PDF content)
14
Nakamura A, Imaizumi A, Yanagawa Y. Beta 2- adrenoceptor function in the kidney. Nippon Yakurigaki zasshi 2004; 124 (6): 427-434
(check this in PDF content)
15
Tinucci T, Abrahao SB, Santello JL, Mion D. Mild chronic renal insufficiency induces sympathetic overactivity. J Hum Hypertens 2001; 15 (6): 401-406
(check this in PDF content)
16
Klein IH, Ligtenberg G, Neumann J et al. Sympathetic nerve activity inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14 (12): 3239-3244
(check this in PDF content)
17
Zoccali C, Mallamaci F, Parlengo S et al. Plasma norepinephrine predict survival and incident cardiovascular events in patients with end stage renal disease. C irculation 2002; 105 (11): 1354-1359
(check this in PDF content)
18
Hansberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end stage renal disease. Circulation 2002; 106 (15): 1974-1979
(check this in PDF content)
19
Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25 (4): 878-882
(check this in PDF content)
20
Ye S, Nosrati S, Campese VM. Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF). J Clin Invest 1997; 99 (3): 540­ 548
(check this in PDF content)
21
Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep 2002; 4 (3): 256-260
(check this in PDF content)
22
Miyajima E, Yamada Y, Yoshida Y et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991; 17 (6): 1057-1062
(check this in PDF content)
23
Modlinger PC, Wilcox CS, Aslam S. Nitric oxide, oxidative stress and progressive of chronic renal failure. Semin Nephrol 2004; 24 (4): 354-365
(check this in PDF content)
24
Campese VM, Shaohua Ye, Huinqin Zhong et al. Reactive oxygen species stimulate central and peripheral sympathetic nervous system. Am J Physiol 2004; 287 (2): H795-H703
(check this in PDF content)
25
Stegbauer J, Vonend O, Obehauser V et al. Angiotensin II receptor modulation of renal vascular resis itance and neurotransmission in young and adult spontaneously hypertensive rats. Kidney Blood Press Res 2005; 28 (1): 20-26
(check this in PDF content)
26
Klein IH, Ligtenberg G, Oey PL et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14 (2): 425-430
(check this in PDF content)
27
Eikelis N, Schlaich M, Aggarwal A et al. Interaction between leptin and human sympathetic nervous system. Hypertension 2003; 41 (5): 1072-1079
(check this in PDF content)
28
Montanaro MS, Allen AM, Oldfield BJ. Structural and functional evidence supporting a role for leptin in central neural pathways influencing blood pressure in rats. Exp Physiol 2005; 90 (5): 689-696
(check this in PDF content)
29
Scharma K, Considine RV, Michael B et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997; 51 (6): 1980-1985
(check this in PDF content)
30
Merabet E, Dagogo-Jack S, Coyne DW et al. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 1999; 82 (3): 847-850
(check this in PDF content)
31
Кузьмин ОБ, Пугаева МО, Чуб СВ, Ландарь ЛН. По­ чечные механизмы эссенциальной гипертонии. Нефроло­ гия 2005; 9 (2): 23-29
(check this in PDF content)
32
Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардио­ ренальный континуум: патогенетические основы превентив­ ной нефрологии. Нефрология 2005; 9 (3): 7-15
(check this in PDF content)
33
Ермаков ЮА, Вишняков НИ, Ковальский ГБ. Хрони­ ческая почечная недостаточность у нефрологических боль­ ных в Санкт-Петербурге по данным патологоанатомических исследований за 1993-2003 годы. Нефрология 2005; 9 (2): 78-82
(check this in PDF content)
34
Denton KM, Shweta A, Flower RL, Anderson WP Predominant postglomerular vascular resistance response to reflex renal nerve stimulation during Ang II clamp in rabbits. Am J Physiol 2004; 287 (4): R780-R786
(check this in PDF content)
35
Luippold G, Beilharz M, Muhlbauer B. Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant 2004; 19 (2): 342-347
(check this in PDF content)
36
Zhang H, Faber JE. Trophic effect of norepinephrine on arterial intima-media and adventicia is augmented by injury and mediated by different ^-adrenoceptor subtypes. Circulat Res 2001; 89 (9): 815-822
(check this in PDF content)
37
Erami C, Zhang H, Tanoue A et al. Adrenergic catecholamine trophic activity contributes to flow-mediated arterial remodeling. Am J Physiol 2005; 289 (2): H744-H753
(check this in PDF content)
38
Johnston RJ, Gordon KL, Suga S et al. Renal injury and salt-sensitive hypertension after exposure to catecholamines. Hypertension 1999; 34 (1): 151-159
(check this in PDF content)
39
Nakamura A, Imaizumi A, Yanagawa Y et al. p2- Adrenoceptor activation attenuates endotoxin-induced acute renal failure. J Am Soc Nephrol 2004; 15 (2): 316-325
(check this in PDF content)
40
Bohlen L, de Courten M, Weidmann P Comparative study of the effects of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7 (9, Pt2): 84S-92S
(check this in PDF content)
41
Gansevoort RT, Sluiter WJ, Hemmelder MH et al. Antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10 (11): 1963-1974
(check this in PDF content)
42
Kalinowski L, Dobrucki LW, Szczeppanska-Konkel M et al. Third-generation beta-blockers stimulate nitric oxide release from epithelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107 (21): 2747-2752
(check this in PDF content)
43
Wong VY, Laping NJ, Nelson AH et al. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. B rit J Pharmacol 2001; 134 (5): 977-984
(check this in PDF content)
44
Branden C, Gabriels M, Vamecq J et al. Carvedilol protects against glomerulosclerosis in the rat remnant kidney without general changes in antioxidant enzyme status. A comparative study of two beta-blocking drugs carvedilol and propranolol. Nephron 1997; 77 (3): 319-324
(check this in PDF content)
45
Rodriques-Peres JC, Losada A, Anabitarte A et al. Effects of novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablation rats. J Pharm acol Exp Ther 1997; 283 (1): 336-344
(check this in PDF content)
46
Tomita K, Marumo F. Effect of long-term carvedolol therapy on renal function in essential hypertension. J Cardiovasc Pharmacol 1992; 19 [Suppl 1]: S97-S101
(check this in PDF content)
47
Zitta S, Stoschitzky K, Zweiker R et al. Dynamic renal function testing by compartmental analysis: assessment of renal functional reserve in essential hypertension. Nephrol Dial Transplant 2000; 15 (8): 1162-1169
(check this in PDF content)
48
Marchi F, Ciriello G. Efficacy of carvedolol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 1995; 12 (4): 212-221
(check this in PDF content)
49
Fassbinder W, Quarter O, Waltz A. Treatment with carvedolol is associated with a significant reduction in microalbuminuria: a multicentre randomized study. In t J Clin Pract 1999; 53 (7): 515-522
(check this in PDF content)
50
Bakris GL, Fonseca V, Katholi RE et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005; 46 (6): 1309-1315
(check this in PDF content)
51
Kramer BK, Ress KM, Erley CM, Risler T. Pharmacokinetic and blood pressure effects of carvedolol in patients with chronic renal failure. Eur J Pharmacol 1992; 43 (1): 85-88
(check this in PDF content)
52
Janssen BJA, Lukoshkova EV, Head GA. Sympathetic modulation of renal blood flow by rilmenidine and captopril: central vs. peripheral effects. Am J Physiol 2002; 282 (1): F113-F123
(check this in PDF content)
53
Smyth DD, Pirnat D, Forzley B, Penner SB. Apparent absence of direct renal effects of imidazoline receptor agonist. Ann NY Acad Sci 2003; 1009 (1): 288-295
(check this in PDF content)
54
Amann K, Rump LC, Simonaviciene A et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11(8): 1469-1478
(check this in PDF content)
55
Vonend O, Apel T, Amann K et al. Modulation of gene expression by moxonidine in rat with chronic renal failure. Nephrol Dial Transplant 2004; 19 (9): 2217-2222
(check this in PDF content)
56
Amann K, Nichols C, Tornig J et al. Effect of ramipril, nifedipine and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996; 11 (6): 1003-1011
(check this in PDF content)
57
Krespi PJ, Makris TK, Hatzizasharias AN et al. Moxonidine effects on microalbuminuria, thrombomodulin and plasminogen activator-I levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12 (5): 463-467
(check this in PDF content)
58
Демидова ТЮ, Аметов АС, Смагина ЛВ, Виноградо­ ва МВ. Органопротективные свойства агониста имидазо- линовых рецепторов моксонидина (физиотенза) у больных артериальной гипертонией и сахарным диабетом 2-го типа. Клин фармакол и тер 2004; 13 (5): 21-25
(check this in PDF content)
59
Трусов ВВ, Аксенов КВ. Влияние агониста имидазо- линовых рецепторов моксонидина на состояние микроцир­ куляции и функцию почек у больных артериальной гипертонией с сахарным диабетом 2-го типа. Кардиология 2003; 43 (9): 44-48
(check this in PDF content)
60
Bauduceau B, Mayaudon H, Dupuy O. Rilmenidine in the hypertensive type 2 diabetic: a controlled pilot study versus captopril. J Cardiovasc Risk 2000; 7 (1): 57-61
(check this in PDF content)
61
Kirch W, Hutt HJ, Planitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15 (4): 245-253
(check this in PDF content)
62
Singlas E, Ehrhardt JD, Zech P et al. Pharmacokinetics of rilmenidine. Am J Cardiol 1988: 61 (7): 54D-59D Поступила в редакцию 14.01.2006 г.
(check this in PDF content)